{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T22:45:14Z","timestamp":1779317114170,"version":"3.51.4"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,1,6]],"date-time":"2022-01-06T00:00:00Z","timestamp":1641427200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,1,6]],"date-time":"2022-01-06T00:00:00Z","timestamp":1641427200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1007\/s40257-021-00667-8","type":"journal-article","created":{"date-parts":[[2022,1,6]],"date-time":"2022-01-06T10:03:22Z","timestamp":1641463402000},"page":"167-176","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Medical Management of Hidradenitis Suppurativa with Non-Biologic Therapy: What\u2019s New?"],"prefix":"10.1007","volume":"23","author":[{"given":"Soha","family":"Ghanian","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mika","family":"Yamanaka-Takaichi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haley B.","family":"Naik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Afsaneh","family":"Alavi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,1,6]]},"reference":[{"key":"667_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2021.01.059","author":"A Garg","year":"2021","unstructured":"Garg A, et al. Comorbidity screening in hidradenitis suppurativa: evidence-based recommendations from the US and Canadian Hidradenitis Suppurativa Foundation. J Am Acad Dermatol. 2021. https:\/\/doi.org\/10.1016\/j.jaad.2021.01.059 (Epub 23 Jan 2021).","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"667_CR2","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s40257-014-0105-5","volume":"16","author":"A Alavi","year":"2015","unstructured":"Alavi A, Anooshirvani N, Kim WB, Coutts P, Sibbald RG. Quality-of-life impairment in patients with hidradenitis suppurativa: a Canadian study. Am J Clin Dermatol. 2015;16(1):61\u20135.","journal-title":"Am J Clin Dermatol"},{"issue":"8","key":"667_CR3","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1001\/jamadermatol.2019.0759","volume":"155","author":"MO Machado","year":"2019","unstructured":"Machado MO, et al. Depression and anxiety in adults with hidradenitis suppurativa: a systematic review and meta-analysis. JAMA Dermatol. 2019;155(8):939\u201345.","journal-title":"JAMA Dermatol"},{"issue":"2","key":"667_CR4","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s40257-020-00579-z","volume":"22","author":"T Abdalla","year":"2021","unstructured":"Abdalla T, Lowes MA, Kaur N, Micheletti RG, Steinhart Ah, Alavi A. Is there a role for therapeutic drug monitoring in patients with hidradenitis suppurativa on tumor necrosis factor-alpha inhibitors. Am J Clin Dermatol. 2021;22(2):139\u201347.","journal-title":"Am J Clin Dermatol"},{"issue":"5","key":"667_CR5","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1007\/s40257-019-00439-5","volume":"20","author":"KS Flood","year":"2019","unstructured":"Flood KS, Porter ML, Kimball AB. Biologic treatment for hidradenitis suppurativa. Am J Clin Dermatol. 2019;20(5):625\u201338. https:\/\/doi.org\/10.1007\/s40257-019-00439-5.","journal-title":"Am J Clin Dermatol"},{"issue":"2","key":"667_CR6","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.jaad.2019.06.1301","volume":"82","author":"A Garg","year":"2020","unstructured":"Garg A, et al. Evaluating patients\u2019 unmet needs in hidradenitis suppurativa: results from the Global Survey of Impact and Healthcare Needs (VOICE) Project. J Am Acad Dermatol. 2020;82(2):366\u201376.","journal-title":"J Am Acad Dermatol"},{"key":"667_CR7","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1111\/jdv.12966","volume":"29","author":"CC Zouboulis","year":"2015","unstructured":"Zouboulis CC, et al. European S1 guideline for the treatment of hidradenitis suppurativa\/acne inversa. J Eur Acad Dermatol Venereol. 2015;29:619\u201344.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"667_CR8","doi-asserted-by":"crossref","first-page":"e175","DOI":"10.1016\/j.jaad.2015.07.026","volume":"73","author":"MJ Danesh","year":"2015","unstructured":"Danesh MJ, Kimball AB. Pyrithione zinc as a general management strategy for hidradenitis suppurativa. J Am Acad Dermatol. 2015;73(5):e175.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"667_CR9","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.jaad.2018.10.063","volume":"80","author":"P Leiphart","year":"2019","unstructured":"Leiphart P, Ma H, Naik HB, Kirby JS. The effect of antimicrobial washes on antibacterial resistance in hidradenitis suppurativa. J Am Acad Dermatol. 2019;80(3):821\u20132.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"667_CR10","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jaad.2019.02.068","volume":"81","author":"A Alikhan","year":"2019","unstructured":"Alikhan A, et al. North American clinical management guidelines for hidradenitis suppurativa: a publication from the United States and Canadian Hidradenitis Suppurativa Foundations: Part II: Topical, intralesional, and systemic medical management. J Am Acad Dermatol. 2019;81(1):91\u2013101.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"667_CR11","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1159\/000500827","volume":"235","author":"P Leiphart","year":"2019","unstructured":"Leiphart P, Kitts S, Kirby JS. Adherence to over-the-counter antimicrobial washes in hidradenitis suppurativa patients. Dermatology. 2019;235(5):440\u20131.","journal-title":"Dermatology"},{"issue":"2","key":"667_CR12","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.jaad.2016.08.001","volume":"76","author":"AH Fischer","year":"2017","unstructured":"Fischer AH, Haskin A, Okoye GA. Patterns of antimicrobial resistance in lesions of hidradenitis suppurativa. J Am Acad Dermatol. 2017;76(2):309\u201313.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"667_CR13","doi-asserted-by":"crossref","first-page":"e13868","DOI":"10.1111\/dth.13868","volume":"33","author":"S Fisher","year":"2020","unstructured":"Fisher S, Ziv M. Efficacy of topical ichthammol 10% for hidradenitis suppurativa: case series and systematic review of its use in dermatology. Dermatol Ther. 2020;33(6):e13868.","journal-title":"Dermatol Ther"},{"key":"667_CR14","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1159\/000477459","volume":"233","author":"RE Hunger","year":"2017","unstructured":"Hunger RE, Laffitte E, Luchli S, et al. Swiss practice recommendations for the management of hidradenitis suppurativa\/acne inversa. Dermatol. 2017;233:113\u20139.","journal-title":"Dermatol"},{"issue":"1","key":"667_CR15","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/j.1365-2230.2009.03377.x","volume":"35","author":"J Boer","year":"2010","unstructured":"Boer J, Jemec GBE. Resorcinol peels as a possible self-treatment of painful nodules in hidradenitis suppurativa. Clin Exp Dermatol. 2010;35(1):36\u201340.","journal-title":"Clin Exp Dermatol"},{"issue":"6","key":"667_CR16","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1111\/bjd.19337","volume":"183","author":"E Molinelli","year":"2020","unstructured":"Molinelli E, et al. Efficacy and safety of topical resorcinol 15% as long-term treatment of mild-to-moderate hidratenitis suppurativa: a valid alternative to clindamycin in the panorama of antibiotic resistance. Br J Dermatol. 2020;183(6):1117\u20139.","journal-title":"Br J Dermatol"},{"key":"667_CR17","doi-asserted-by":"publisher","DOI":"10.1159\/000515450","author":"A Docampo-Sim\u00f3n","year":"2021","unstructured":"Docampo-Sim\u00f3n A, et al. Topical 15% resorcinol is associated with high treatment satisfaction in patients with mild to moderate hidradenitis suppurativa. Dermatology. 2021. https:\/\/doi.org\/10.1159\/000515450 (Epub 22 Apr 2021).","journal-title":"Dermatology"},{"key":"667_CR18","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/j.jaad.2016.06.049","volume":"75","author":"PT Riis","year":"2016","unstructured":"Riis PT, Boer J, Prens EP, et al. Intralesional triamcinolone for flares of hidradenitis suppurativa(HS): a case series. J Am Acad Dermatol. 2016;75:1151\u20135.","journal-title":"J Am Acad Dermatol"},{"key":"667_CR19","doi-asserted-by":"crossref","first-page":"8018192","DOI":"10.1155\/2017\/8018192","volume":"2017","author":"VK Shanmugam","year":"2017","unstructured":"Shanmugam VK, Zaman NM, McNish S, Hant FN. Review of current immunologic therapies for hidradenitis suppurativa. Int J Rheumatol. 2017;2017:8018192.","journal-title":"Int J Rheumatol"},{"key":"667_CR20","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1080\/13543784.2018.1412430","volume":"27","author":"P Theut Riis","year":"2018","unstructured":"Theut Riis P, Thorlacius LR, Jemec GB. Investigational drugs in clinical trials for hidradenitis suppurativa. Expert Opin Investig Drugs. 2018;27:43\u201353.","journal-title":"Expert Opin Investig Drugs"},{"issue":"5","key":"667_CR21","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1097\/DSS.0000000000002112","volume":"46","author":"K Fajgenbaum","year":"2020","unstructured":"Fajgenbaum K, Crouse L, Dong L, Zeng D, Sayed C. Intralesional triamcinolone may not be beneficial for treating acute hidradenitis suppurativa lesions: a double-blind randomized, placebo controlled trial. Dermatol Surg. 2020;46(5):685\u20139.","journal-title":"Dermatol Surg"},{"issue":"6","key":"667_CR22","first-page":"e13901","volume":"33","author":"L Fania","year":"2020","unstructured":"Fania L, et al. Intralesional ultrasound-guided combined treatment with triamcinolone plus lincomycin in hidradenitis suppurativa: a pilot study. Dermatol Ther. 2020;33(6):e13901.","journal-title":"Dermatol Ther"},{"issue":"6","key":"667_CR23","doi-asserted-by":"crossref","first-page":"e14116","DOI":"10.1111\/dth.14116","volume":"33","author":"RD Caposiena Caro","year":"2020","unstructured":"Caposiena Caro RD, Tartaglia C, Pensa C, Bianchi L. Intralesional therapy under ultrasound guidance in hidradenitis suppurativa: the importance of ultrasound evaluation. Dermatol Ther. 2020;33(6):e14116.","journal-title":"Dermatol Ther"},{"issue":"10","key":"667_CR24","doi-asserted-by":"crossref","first-page":"13363","DOI":"10.1038\/s41598-020-70176-x","volume":"7","author":"L Salvador-Rodriguez","year":"2020","unstructured":"Salvador-Rodriguez L, Arias-Santiago S, Molina-Leyva A. Ultrasound-assisted intralesional corticosteroid infiltrations for patients with hidradenitis suppurativa. Sci Rep. 2020;7(10):13363.","journal-title":"Sci Rep"},{"issue":"3","key":"667_CR25","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1080\/09546634.2019.1655524","volume":"32","author":"FJ Garc\u00eda-Mart\u00ednez","year":"2021","unstructured":"Garc\u00eda-Mart\u00ednez FJ, et al. Intralesional corticosteroid injection for the treatment of hidradenitis suppurativa: a multicenter retrospective clinical study. J Dermatolog Treatment. 2021;32(3):286\u201390.","journal-title":"J Dermatolog Treatment."},{"issue":"12","key":"667_CR26","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1016\/j.jdcr.2020.10.004","volume":"6","author":"CN Dautriche","year":"2020","unstructured":"Dautriche CN, et al. Tumescent triamcinolone infiltration: a new approach for the management of recalcitrant hidradenitis suppurativa. JAAD Case Rep. 2020;6(12):1310\u20132.","journal-title":"JAAD Case Rep."},{"issue":"6","key":"667_CR27","doi-asserted-by":"crossref","first-page":"e381","DOI":"10.1111\/jdv.17151","volume":"35","author":"M Arenbergerova","year":"2021","unstructured":"Arenbergerova M, et al. Corticosteroid rescue therapy in relapsing hidradenitis suppurativa treated with adalimumab. J Eur Acad Dermatol Venereol. 2021;35(6):e381\u20133.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"667_CR28","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010081.pub2","author":"JR Ingram","year":"2015","unstructured":"Ingram JR, et al. Interventions for hidradenitis suppurativa. Cochrane Database Syst Rev. 2015. https:\/\/doi.org\/10.1002\/14651858.CD010081.pub2.","journal-title":"Cochrane Database Syst Rev"},{"issue":"9","key":"667_CR29","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1001\/jamadermatol.2017.0904","volume":"153","author":"HC Ring","year":"2017","unstructured":"Ring HC, et al. The follicular skin microbiome in patients with hidradenitis suppurativa and healthy controls. JAMA Derm. 2017;153(9):897\u2013905.","journal-title":"JAMA Derm"},{"issue":"3","key":"667_CR30","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1111\/ced.14512","volume":"46","author":"S Kitts","year":"2021","unstructured":"Kitts S, Govea R, Maczuga S, Kirby J. Long-term antibiotic use for the treatment of hidradenitis suppurativa consistent with guideline recommendations. Clin Exp Dermatol. 2021;46(3):582\u20133.","journal-title":"Clin Exp Dermatol"},{"issue":"5","key":"667_CR31","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1080\/17512433.2020.1762571","volume":"13","author":"C Marasca","year":"2021","unstructured":"Marasca C, et al. The pharmacology of antibiotic therapy in hidradenitis suppurativa. Expert Rev Clin Pharmacol. 2021;13(5):521\u201330.","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"3","key":"667_CR32","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/ijd.13428","volume":"56","author":"K Armyra","year":"2017","unstructured":"Armyra K, Kouris A, Markantoni V, Katsambas A, Kontochristopoulos G. Hidradenitis suppurativa treated with tetracycline in combination with colchicine: a prospective series of 20 patients. Int J Dermatol. 2017;56(3):346\u201350.","journal-title":"Int J Dermatol"},{"issue":"7","key":"667_CR33","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1111\/ijd.15459","volume":"60","author":"AHR Jorgensen","year":"2021","unstructured":"Jorgensen AHR, Yao Y, Thomsen SF, Ring HS. Treatment of hidradenitis suppurativa with tetracycline, doxycycline, or lymecycline: a prospective study. Int J Dermatol. 2021;60(7):785\u201391. https:\/\/doi.org\/10.1111\/ijd.15459.","journal-title":"Int J Dermatol"},{"issue":"2","key":"667_CR34","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1159\/000228337","volume":"219","author":"HH van der Zee","year":"2009","unstructured":"van der Zee HH, Boer J, Prens EP, Jemec GBE. The effect of combined treatment with oral clindamycin and oral rifampicin in patients with hidradenitis suppurativa. DermatologyTet. 2009;219(2):143\u20137.","journal-title":"DermatologyTet."},{"issue":"5","key":"667_CR35","doi-asserted-by":"crossref","first-page":"469","DOI":"10.4103\/0019-5154.190105","volume":"61","author":"S Pradhan","year":"2016","unstructured":"Pradhan S, Madke B, Kabra P, Singh AL. Anti-inflammatory and immunomodulatory effects of antibiotics and their use in dermatology. Indian J Dermatol. 2016;61(5):469\u201381.","journal-title":"Indian J Dermatol"},{"issue":"4","key":"667_CR36","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.anplas.2017.03.012","volume":"62","author":"E Robert","year":"2017","unstructured":"Robert E, et al. Non-surgical treatments for hidradenitis suppurativa: a systematic review. Ann Chir Plast Esthet. 2017;62(4):274\u201394.","journal-title":"Ann Chir Plast Esthet"},{"issue":"3","key":"667_CR37","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1111\/bjd.19578","volume":"184","author":"Y Yao","year":"2021","unstructured":"Yao Y, J\u00f8rgensen AR, Ring HC, Thomsen SF. Effectiveness of clindamycin and rifampicin combination therapy in hidradenitis suppurativa: a 6-month prospective study. Br J Dermatol. 2021;184(3):552\u20133.","journal-title":"Br J Dermatol"},{"issue":"1","key":"667_CR38","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1111\/bjd.19867","volume":"185","author":"V Bettoli","year":"2021","unstructured":"Bettoli V, Toni G, Odorici G, Forconi R, Corazza M. Oral clindamycin and rifampicin the treatment of hidradenitis suppurativa-acne inversa in patients of pediatric age: a pilot prospective study. Br J Dermatol. 2021;185(1):216\u20137. https:\/\/doi.org\/10.1111\/bjd.19867.","journal-title":"Br J Dermatol"},{"issue":"2","key":"667_CR39","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.jaad.2020.12.089","volume":"85","author":"KR van Straalen","year":"2021","unstructured":"van Straalen KR, et al. The efficacy and tolerability of tetracyclines and clindamycin plus rifampicin for the treatment of hidradenitis suppurativa; results of a prospective European cohort study. J Am Acad Dermatol. 2021;85(2):369\u201378. https:\/\/doi.org\/10.1016\/j.jaad.2020.12.089.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"667_CR40","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1111\/ced.14388","volume":"46","author":"RD Caposiena Caro","year":"2021","unstructured":"Caposiena Caro RD, Molinelli E, Brisigotti V, Offidani A, Bianchi L. Lymecycline vs. clindamycin plus rifampicin in hidradenitis suppurativa treatment: clinical and ultrasonography evaluation. Clin Exp Dermatol. 2021;46(1):96\u2013102.","journal-title":"Clin Exp Dermatol"},{"issue":"5","key":"667_CR41","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1016\/j.jaad.2018.11.035","volume":"80","author":"RD Caposiena Caro","year":"2019","unstructured":"Caposiena Caro RD, et al. Clindamycin versus clindamycin plus rifampicin in hidradenitis suppurativa treatment: clinical and ultrasound observations. J Am Acad Dermatol. 2019;80(5):1314\u201321.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"667_CR42","doi-asserted-by":"crossref","first-page":"e12792","DOI":"10.1111\/dth.12792","volume":"32","author":"E Rosi","year":"2019","unstructured":"Rosi E, et al. Clindamycin as unique antibiotic choice in hidradenitis suppurativa. Dermatol Ther. 2019;32(2):e12792.","journal-title":"Dermatol Ther"},{"issue":"9","key":"667_CR43","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1093\/jac\/dkt129","volume":"68","author":"A Deshpande","year":"2013","unstructured":"Deshpande A, et al. Community-associated Clostridium difficile infection and antibiotics: a meta-analysis. J Antimicrob Chemother. 2013;68(9):1951\u201361.","journal-title":"J Antimicrob Chemother"},{"key":"667_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.01.007","author":"M Delage","year":"2020","unstructured":"Delage M, et al. Rifampin-moxifloxacin-metronidazole combination therapy for severe Hurley Stage 1 hidradenitis suppurativa: prospective short-term trial and one-year follow-up in 28 consecutive patients. J Am Acad Dermatol. 2020. https:\/\/doi.org\/10.1016\/j.jaad.2020.01.007 (Epub 10 Jan 2020).","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"667_CR45","first-page":"e323","volume":"35","author":"HC Ring","year":"2021","unstructured":"Ring HC, Knudsen A, Thomsen SF. Metronidazole for hidradenitis suppurativa: future potential treatment applications. J Eur Acad Dermatol Venereol. 2021;35(5):e323\u20134.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"667_CR46","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1086\/340348","volume":"34","author":"DR Graham","year":"2002","unstructured":"Graham DR, et al. Ertapenem once daily versus piperacillin-tazobactam 4 times per day for treatment of complicated skin and skin-structure infections in adults: results of a prospective, randomized, double-blind multicenter study. Clin Infect Dis. 2002;34:1460\u20138.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"667_CR47","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1093\/jac\/dkv361","volume":"71","author":"O Join-Lambert","year":"2016","unstructured":"Join-Lambert O, et al. Efficacy of ertapenem in severe hidradenitis suppurativa: a pilot study in a cohort of 30 consecutive patients. J Antimicrob Chemother. 2016;71(2):513\u201320.","journal-title":"J Antimicrob Chemother"},{"issue":"4","key":"667_CR48","doi-asserted-by":"crossref","first-page":"E88","DOI":"10.1111\/ijd.14329","volume":"58","author":"AB Lyons","year":"2019","unstructured":"Lyons AB, Parks-Miller A, Zubair R, Hamzavi IH. Ertapenem\u2014a potent treatment for clinical and quality of life improvement in patients with hidradenitis suppurative\u2014reply. Int J Dermatol. 2019;58(4):E88.","journal-title":"Int J Dermatol"},{"issue":"5","key":"667_CR49","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1159\/000329023","volume":"222","author":"S Yazdanyar","year":"2011","unstructured":"Yazdanyar S, Boer J, Ingvarsson G, Szepietowski JC, Jemec GB. Dapsone therapy for hidradenitis suppurativa: a series of 24 patients. Dermatology. 2011;222(5):342\u20136.","journal-title":"Dermatology"},{"issue":"4","key":"667_CR50","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1111\/bjd.19136","volume":"183","author":"G Murray","year":"2020","unstructured":"Murray G, Hollywood A, Kirby B, Hughes R. Dapsone therapy for hidradenitis suppurativa. Br J Dermatol. 2020;183(4):767\u20138.","journal-title":"Br J Dermatol"},{"issue":"4","key":"667_CR51","first-page":"239","volume":"24","author":"PT Riis","year":"2016","unstructured":"Riis PT, Ring HC, Themstrup L, Jemec GB. The role of androgens and estrogens in hidradenitis suppurative\u2014a systematic review. Acta Dermatovenerol Croat. 2016;24(4):239\u201349.","journal-title":"Acta Dermatovenerol Croat"},{"issue":"1","key":"667_CR52","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.jaad.2016.07.024","volume":"76","author":"AR Vossen","year":"2017","unstructured":"Vossen AR, van Straalen KR, Prens EP, van der Zee HH. Menses and pregnancy affect symptoms in hidradenitis suppurativa: a cross-sectional study. J Am Acad Dermatol. 2017;76(1):155\u20136.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"667_CR53","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1111\/j.1365-2133.1986.tb05740.x","volume":"115","author":"PS Mortimer","year":"1986","unstructured":"Mortimer PS, Dawber RP, Gales MA, Moore RA. A double-blind controlled cross-over trial of cyproterone acetate in females with hidradenitis suppurativa. Br J Dermatol. 1986;115(3):263\u20138.","journal-title":"Br J Dermatol"},{"issue":"3","key":"667_CR54","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s11154-016-9366-z","volume":"17","author":"I Karagiannidis","year":"2016","unstructured":"Karagiannidis I, Nikolakis G, Sabat R, Zouboulis CC. Hidradenitis suppurativa\/acne inversa: an endocrine skin disorder? Rev Endocr Metab Disord. 2016;17(3):335\u201341.","journal-title":"Rev Endocr Metab Disord"},{"issue":"1","key":"667_CR55","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.jaad.2018.06.063","volume":"80","author":"NM Golbari","year":"2019","unstructured":"Golbari NM, Porter ML, Kimball AB. Antiandrogen therapy with spironolactone for the treatment of hidradenitis suppurativa. J Am Acad Dermatol. 2019;80(1):114\u20139.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"667_CR56","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1111\/ced.14119","volume":"45","author":"C Quinlan","year":"2020","unstructured":"Quinlan C, Kirby B, Hughes R. Spironolactone therapy for hidradenitis suppurativa. Clin Exp Dermatol. 2020;45(4):464\u20135.","journal-title":"Clin Exp Dermatol"},{"issue":"3","key":"667_CR57","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1080\/09546634.2019.1592100","volume":"31","author":"L Jennings","year":"2020","unstructured":"Jennings L, Hambly R, Hughes R, Moriarty B, Kirby B. Metformin use in hidradenitis suppurativa. J Dermatol Treat. 2020;31(3):261\u20134.","journal-title":"J Dermatol Treat"},{"issue":"4","key":"667_CR58","doi-asserted-by":"crossref","first-page":"125","DOI":"10.2310\/7750.2007.00019","volume":"11","author":"JN Kraft","year":"2007","unstructured":"Kraft JN, Searles GE. Hidradenitis suppurativa in 64 female patients: retrospective study comparing oral antibiotics and antiandrogen therapy. J Cutan Med Surg. 2007;11(4):125\u201331.","journal-title":"J Cutan Med Surg"},{"issue":"12","key":"667_CR59","first-page":"1231","volume":"19","author":"C Moussa","year":"2020","unstructured":"Moussa C, Wadowski L, Price H, Mirea L, O\u2019Haver J. Metforin as adjunctive therapy for pediatric patients with hidradenitis suppurativa. J Drugs Deramtol. 2020;19(12):1231\u20134.","journal-title":"J Drugs Deramtol."},{"issue":"4","key":"667_CR60","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.jaad.2008.11.911","volume":"60","author":"A Alikhan","year":"2009","unstructured":"Alikhan A, Lynch PJ, Eisen DB. Hidradenitis suppurativa: a comprehensive review. J Am Acad Dermatol. 2009;60(4):539\u201361.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"667_CR61","doi-asserted-by":"crossref","first-page":"e178","DOI":"10.1111\/bjd.16768","volume":"183","author":"KR van Straalen","year":"2020","unstructured":"van Straalen KR, Schneider-Burrus S, Prens EP. Current and future treatment of hidradenitis suppurativa. Br J Dermatol. 2020;183(6):e178\u201387.","journal-title":"Br J Dermatol"},{"issue":"4","key":"667_CR62","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1080\/09546634.2019.1670779","volume":"32","author":"N Patel","year":"2021","unstructured":"Patel N, et al. Isotretinoin in the treatment of hidradenitis suppurativa: a retrospective study. J Dermatol Treat. 2021;32(4):473\u20135.","journal-title":"J Dermatol Treat"},{"issue":"3","key":"667_CR63","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1177\/1203475418823529","volume":"23","author":"ML McPhie","year":"2019","unstructured":"McPhie ML, Bridgman AC, Kirchhof MG. Combination therapies for hidradenitis suppurativa: a retrospective chart review of 31 patients. J Cutan Med Surg. 2019;23(3):270\u20136.","journal-title":"J Cutan Med Surg"},{"key":"667_CR64","doi-asserted-by":"crossref","first-page":"597","DOI":"10.2165\/00003495-199243040-00010","volume":"43","author":"T Pilkington","year":"1992","unstructured":"Pilkington T, Brogden RN. Acitretin: a review of its pharmacology and therapeutic use. Drugs. 1992;43:597\u2013627.","journal-title":"Drugs"},{"issue":"4","key":"667_CR65","first-page":"287","volume":"69","author":"AJ Scheman","year":"2002","unstructured":"Scheman AJ. Nodulocystic acne and hidradenitis suppurativa treated with acitretin: a case report. Cutis. 2002;69(4):287\u20138.","journal-title":"Cutis"},{"issue":"1","key":"667_CR66","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s40257-019-00484-0","volume":"21","author":"S Dhaliwal","year":"2020","unstructured":"Dhaliwal S, et al. Effects of zinc supplementation on inflammatory skin diseases: a systematic review of clinical evidence. Am J Clin Dermatol. 2020;21(1):21\u201339.","journal-title":"Am J Clin Dermatol"},{"issue":"2","key":"667_CR67","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.jaad.2020.04.092","volume":"83","author":"E Molinelli","year":"2020","unstructured":"Molinelli E, et al. Efficacy of oral zinc and nicotinamide as maintenance therapy for mild\/moderate hidradenitis suppurativa: a controlled retrospective clinical study. J Am Acad Dermatol. 2020;83(2):665\u20137.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"667_CR68","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1111\/fcp.12403","volume":"33","author":"ML Laroche","year":"2019","unstructured":"Laroche ML, Teste M, Vanoost J, Geniaux H. Successful control of hidradenitis suppurativa with verapamil: a case report. Fundam Clin Pharmacol. 2019;33(1):122\u20134.","journal-title":"Fundam Clin Pharmacol"},{"issue":"12","key":"667_CR69","first-page":"1170","volume":"99","author":"C Hotz","year":"2019","unstructured":"Hotz C, Sbidian E, Oro SIH, Chosidow O, Wolkensein P. Thalidomide in severe hidradenitis suppurativa: a therapeutic option. Acta Derm Venereol. 2019;99(12):1170\u20131.","journal-title":"Acta Derm Venereol"}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-021-00667-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40257-021-00667-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-021-00667-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,10]],"date-time":"2022-03-10T10:22:50Z","timestamp":1646907770000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40257-021-00667-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,6]]},"references-count":69,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["667"],"URL":"https:\/\/doi.org\/10.1007\/s40257-021-00667-8","relation":{},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"value":"1175-0561","type":"print"},{"value":"1179-1888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,6]]},"assertion":[{"value":"8 December 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No sources of funding were used to assist in the preparation of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Soha Ghanian, Mika Yamanaka-Takaichi, and Haley B. Naik have no conflicts of interest to disclose. Afsaneh Alavi is a consultant for Abbvie, Boehringer Ingelheim, Janssen, InflaRx, Novartis, and UCB.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interests\/Competing interests"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate\/publish"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"SG and MYT performed the literature review, and MYT, HBN, and AA edited the manuscript.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}